Journal of Nanobiotechnology, Год журнала: 2024, Номер 22(1)

Опубликована: Ноя. 30, 2024

Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk liver carcinoma, several obstacles still hinder their effectiveness. These include resistance, prolonged treatment duration, low efficacy in clearing antigens. To address these challenges HBV treatment, numerous approaches have been developed with remarkable success. Among strategies, small-interfering RNA (siRNA) stands out as one most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, unable cross cell membrane due large, anionic structure. Therefore, effective delivery systems required protect maintain functionality. In this review, we discussed promises siRNA therapy treating HBV, milestones systems, products that entered clinical trials. Finally, outlined future perspectives siRNA-based treatment.

Язык: Английский